260 related articles for article (PubMed ID: 26489460)
41. Anti-OX40L monoclonal antibody prolongs secondary heart allograft survival based on CD40/CD40L and LFA-1/ICAM-1 blockade.
Dai H; Peng F; Lin M; Xia J; Yu S; Lan G; Wang Y; Xie X; Fang C; Corbascio M; Qi Z; Peng L
Transpl Immunol; 2015 Mar; 32(2):84-91. PubMed ID: 25613092
[TBL] [Abstract][Full Text] [Related]
42. Interleukin-9 promotes eosinophilic rejection of mouse heart allografts.
Poulin LF; Richard M; Le Moine A; Kiss R; McKenzie AN; Goldman M; Renauld JC; Van Snick J; Braun MY
Transplantation; 2003 Aug; 76(3):572-7. PubMed ID: 12923446
[TBL] [Abstract][Full Text] [Related]
43. The Critical Role of Induced CD4+ FoxP3+ Regulatory Cells in Suppression of Interleukin-17 Production and Attenuation of Mouse Orthotopic Lung Allograft Rejection.
Zhou W; Zhou X; Gaowa S; Meng Q; Zhan Z; Liu J; Li J; Fan H; Liu Z
Transplantation; 2015 Jul; 99(7):1356-64. PubMed ID: 25856405
[TBL] [Abstract][Full Text] [Related]
44. Generation of therapeutic dendritic cells and regulatory T cells for preventing allogeneic cardiac graft rejection.
Zhang X; Li M; Lian D; Zheng X; Zhang ZX; Ichim TE; Xia X; Huang X; Vladau C; Suzuki M; Garcia B; Jevnikar AM; Min WP
Clin Immunol; 2008 Jun; 127(3):313-21. PubMed ID: 18358783
[TBL] [Abstract][Full Text] [Related]
45. Targeting age-specific changes in CD4
Nian Y; Iske J; Maenosono R; Minami K; Heinbokel T; Quante M; Liu Y; Azuma H; Yang J; Abdi R; Zhou H; Elkhal A; Tullius SG
Aging Cell; 2021 Feb; 20(2):e13299. PubMed ID: 33497523
[TBL] [Abstract][Full Text] [Related]
46. The role of glutamine and glucose analogues in metabolic inhibition of human myeloid leukaemia in vitro.
Griffiths M; Keast D; Patrick G; Crawford M; Palmer TN
Int J Biochem; 1993 Dec; 25(12):1749-55. PubMed ID: 8138012
[TBL] [Abstract][Full Text] [Related]
47. Sensitivity to Restimulation-Induced Cell Death Is Linked to Glycolytic Metabolism in Human T Cells.
Larsen SE; Bilenkin A; Tarasenko TN; Arjunaraja S; Stinson JR; McGuire PJ; Snow AL
J Immunol; 2017 Jan; 198(1):147-155. PubMed ID: 27852741
[TBL] [Abstract][Full Text] [Related]
48. Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug.
Rais R; Lemberg KM; Tenora L; Arwood ML; Pal A; Alt J; Wu Y; Lam J; Aguilar JMH; Zhao L; Peters DE; Tallon C; Pandey R; Thomas AG; Dash RP; Seiwert T; Majer P; Leone RD; Powell JD; Slusher BS
Sci Adv; 2022 Nov; 8(46):eabq5925. PubMed ID: 36383674
[TBL] [Abstract][Full Text] [Related]
49. We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of
Lemberg KM; Vornov JJ; Rais R; Slusher BS
Mol Cancer Ther; 2018 Sep; 17(9):1824-1832. PubMed ID: 30181331
[TBL] [Abstract][Full Text] [Related]
50. A redox-responsive prodrug for tumor-targeted glutamine restriction.
Prange CJ; Sayed NYB; Feng B; Goepfert C; Trujillo DO; Hu X; Tang L
J Control Release; 2024 Apr; 368():251-264. PubMed ID: 38403173
[TBL] [Abstract][Full Text] [Related]
51. Harnessing Immune Cell Metabolism to Modulate Alloresponse in Transplantation.
Noble J; Macek Jilkova Z; Aspord C; Malvezzi P; Fribourg M; Riella LV; Cravedi P
Transpl Int; 2024; 37():12330. PubMed ID: 38567143
[TBL] [Abstract][Full Text] [Related]
52. Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems.
Yokoyama Y; Estok TM; Wild R
Mol Cancer Ther; 2022 Oct; 21(10):1561-1572. PubMed ID: 35930753
[TBL] [Abstract][Full Text] [Related]
53. Tumor cells and memory T cells converge at glycolysis: therapeutic implications.
Karthikeyan S; Geschwind JF; Ganapathy-Kanniappan S
Cancer Biol Ther; 2014 May; 15(5):483-5. PubMed ID: 24556820
[TBL] [Abstract][Full Text] [Related]
54. ERK Inhibition Promotes Engraftment of Allografts by Reprogramming T-Cell Metabolism.
Tan X; Qi C; Zhao X; Sun L; Wu M; Sun W; Gu L; Wang F; Feng H; Huang X; Xie B; Shi Z; Xie P; Wu M; Zhang Y; Chen G
Adv Sci (Weinh); 2023 Jun; 10(16):e2206768. PubMed ID: 37013935
[TBL] [Abstract][Full Text] [Related]
55. The role of metabolic reprogramming in T cell fate and function.
Patsoukis N; Bardhan K; Weaver J; Herbel C; Seth P; Li L; Boussiotis VA
Curr Trends Immunol; 2016; 17():1-12. PubMed ID: 28356677
[TBL] [Abstract][Full Text] [Related]
56. Asymmetric inheritance of mTORC1 kinase activity during division dictates CD8(+) T cell differentiation.
Pollizzi KN; Sun IH; Patel CH; Lo YC; Oh MH; Waickman AT; Tam AJ; Blosser RL; Wen J; Delgoffe GM; Powell JD
Nat Immunol; 2016 Jun; 17(6):704-11. PubMed ID: 27064374
[TBL] [Abstract][Full Text] [Related]
57. Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction.
Zhao E; Maj T; Kryczek I; Li W; Wu K; Zhao L; Wei S; Crespo J; Wan S; Vatan L; Szeliga W; Shao I; Wang Y; Liu Y; Varambally S; Chinnaiyan AM; Welling TH; Marquez V; Kotarski J; Wang H; Wang Z; Zhang Y; Liu R; Wang G; Zou W
Nat Immunol; 2016 Jan; 17(1):95-103. PubMed ID: 26523864
[TBL] [Abstract][Full Text] [Related]
58. Targeting CD8 T-Cell Metabolism in Transplantation.
Yap M; Brouard S; Pecqueur C; Degauque N
Front Immunol; 2015; 6():547. PubMed ID: 26557123
[TBL] [Abstract][Full Text] [Related]
59. The cytotoxic T cell proteome and its shaping by the kinase mTOR.
Hukelmann JL; Anderson KE; Sinclair LV; Grzes KM; Murillo AB; Hawkins PT; Stephens LR; Lamond AI; Cantrell DA
Nat Immunol; 2016 Jan; 17(1):104-12. PubMed ID: 26551880
[TBL] [Abstract][Full Text] [Related]
60. Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy.
Sukumar M; Liu J; Mehta GU; Patel SJ; Roychoudhuri R; Crompton JG; Klebanoff CA; Ji Y; Li P; Yu Z; Whitehill GD; Clever D; Eil RL; Palmer DC; Mitra S; Rao M; Keyvanfar K; Schrump DS; Wang E; Marincola FM; Gattinoni L; Leonard WJ; Muranski P; Finkel T; Restifo NP
Cell Metab; 2016 Jan; 23(1):63-76. PubMed ID: 26674251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
